Remicade (infliximab) growth will continue in face of Abbott's roll out of Humira, Johnson & Johnson says. "We expect to see continued solid growth through the balance of this year, and we expect to be able to compete very effectively with both Humira and Enbrel," J&J Company Group Chairman in Charge of Biologics Franchise Joseph Scodari says. "Remicade is likely the most potent drug in this category, and that is by far and away the focal point of our clinical positioning," Scodari adds. U.S. Remicade sales were $345 mil. for the first quarter, a 46% increase...
You may also be interested in...
The risk of inadvertently growing SARS-CoV-2 virus in cell and gene therapies and possibly infecting patients and workers should be assessed and mitigated, the agency advises.
Move was meant to preempt others’ efforts to secure the next six months of Regeneron’s COVID-19 antibody therapeutic.
The company is optimistic about a significant portion of eligible patients opting for its newly approved long-acting HIV therapy over daily, oral antiviral therapy.